BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan

2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan
Treatment and conditionWhere it standsTrials
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1